These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 20829621

  • 1. Neuropsychiatric disorders in Cushing's syndrome.
    Pereira AM, Tiemensma J, Romijn JA.
    Neuroendocrinology; 2010; 92 Suppl 1():65-70. PubMed ID: 20829621
    [Abstract] [Full Text] [Related]

  • 2. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.
    Castinetti F, Conte-Devolx B, Brue T.
    Neuroendocrinology; 2010; 92 Suppl 1():125-30. PubMed ID: 20829633
    [Abstract] [Full Text] [Related]

  • 3. Mifepristone: treatment of Cushing's syndrome.
    Sartor O, Cutler GB.
    Clin Obstet Gynecol; 1996 Jun; 39(2):506-10. PubMed ID: 8734015
    [Abstract] [Full Text] [Related]

  • 4. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.
    Castinetti F, Brue T, Conte-Devolx B.
    Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):295-9. PubMed ID: 22543346
    [Abstract] [Full Text] [Related]

  • 5. Mifepristone for management of Cushing's syndrome.
    Morgan FH, Laufgraben MJ.
    Pharmacotherapy; 2013 Mar; 33(3):319-29. PubMed ID: 23436494
    [Abstract] [Full Text] [Related]

  • 6. Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol.
    Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM.
    Q J Med; 1979 Jul; 48(191):465-72. PubMed ID: 542586
    [Abstract] [Full Text] [Related]

  • 7. Management of diabetes mellitus in Cushing's syndrome.
    Munir A, Newell-Price J.
    Neuroendocrinology; 2010 Jul; 92 Suppl 1():82-5. PubMed ID: 20829624
    [Abstract] [Full Text] [Related]

  • 8. Psychiatric phenomenology in Cushing's disease.
    Loosen PT, Chambliss B, DeBold CR, Shelton R, Orth DN.
    Pharmacopsychiatry; 1992 Jul; 25(4):192-8. PubMed ID: 1528959
    [Abstract] [Full Text] [Related]

  • 9. The use of mifepristone in the treatment of Cushing's syndrome.
    Carroll T, Findling JW.
    Drugs Today (Barc); 2012 Aug; 48(8):509-18. PubMed ID: 22916338
    [Abstract] [Full Text] [Related]

  • 10. Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment.
    Sonino N, Fava GA.
    CNS Drugs; 2001 Aug; 15(5):361-73. PubMed ID: 11475942
    [Abstract] [Full Text] [Related]

  • 11. Chronic glucocorticoid hypersecretion in Cushing's syndrome exacerbates cognitive aging.
    Michaud K, Forget H, Cohen H.
    Brain Cogn; 2009 Oct; 71(1):1-8. PubMed ID: 19428166
    [Abstract] [Full Text] [Related]

  • 12. Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome.
    Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Wägner AM, Rodriguez-Espinosa J, Farrerons J, Webb SM.
    J Bone Miner Res; 2009 Nov; 24(11):1841-6. PubMed ID: 19453254
    [Abstract] [Full Text] [Related]

  • 13. Neuropsychiatric manifestations of patients with Cushing's syndrome. Relationship to cortisol and adrenocorticotropic hormone levels.
    Starkman MN, Schteingart DE.
    Arch Intern Med; 1981 Feb; 141(2):215-9. PubMed ID: 6257194
    [Abstract] [Full Text] [Related]

  • 14. Antiglucocorticoid therapies in major depression: a review.
    Murphy BE.
    Psychoneuroendocrinology; 1997 Feb; 22 Suppl 1():S125-32. PubMed ID: 9264159
    [Abstract] [Full Text] [Related]

  • 15. Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient.
    Banerjee RR, Marina N, Katznelson L, Feldman BJ.
    Pediatrics; 2015 Nov; 136(5):e1377-81. PubMed ID: 26459648
    [Abstract] [Full Text] [Related]

  • 16. Cognitive function and cerebral assessment in patients who have Cushing's syndrome.
    Bourdeau I, Bard C, Forget H, Boulanger Y, Cohen H, Lacroix A.
    Endocrinol Metab Clin North Am; 2005 Jun; 34(2):357-69, ix. PubMed ID: 15850847
    [Abstract] [Full Text] [Related]

  • 17. Personality characteristics and quality of life in patients treated for Cushing's syndrome.
    Sonino N, Bonnini S, Fallo F, Boscaro M, Fava GA.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):314-8. PubMed ID: 16487442
    [Abstract] [Full Text] [Related]

  • 18. Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.
    Fein HG, Vaughan TB, Kushner H, Cram D, Nguyen D.
    BMC Endocr Disord; 2015 Oct 27; 15():63. PubMed ID: 26507877
    [Abstract] [Full Text] [Related]

  • 19. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.
    Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB, Biller BM.
    Endocr Pract; 2013 Oct 27; 19(2):313-26. PubMed ID: 23337135
    [Abstract] [Full Text] [Related]

  • 20. Mifepristone. Auxiliary therapeutic use in cancer and related disorders.
    Koide SS.
    J Reprod Med; 1998 Jul 27; 43(7):551-60. PubMed ID: 9693404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.